GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Cash per Share

Egyptian International Pharmaceutical Investments (CAI:PHAR) Cash per Share : E£4.54 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Egyptian International Pharmaceutical Investments's Cash per Share for the quarter that ended in Dec. 2023 was E£4.54.


Egyptian International Pharmaceutical Investments Cash per Share Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Cash per Share Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.57 5.78 2.42 3.75 4.54

Egyptian International Pharmaceutical Investments Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.75 5.69 4.46 4.48 4.54

Egyptian International Pharmaceutical Investments Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Egyptian International Pharmaceutical Investments's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Egyptian International Pharmaceutical Investments's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Egyptian International Pharmaceutical Investments Cash per Share Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.